Scipher Medicine’s Post

Thrilled to announce our partnership with Scipher Medicine! Together we will transform the autoimmune space by combining the powerful clinical data of OMNY Health's national network with the rich genomic insights from PrismRA, a personalized blood test for #rheumatoidarthritis. Looking forward to this seeing this novel precision medicine collaboration fueling the development of more targeted therapies and improving overall patient outcomes for #autoimmune patients.

Scipher Medicine and Atropos Health announced a strategic partnership to accelerate precision medicine and expand the Immunology Multimodal Network, advancing shared decision-making for patients with rheumatoid arthritis. This collaboration will leverage Scipher's unique data and intelligence derived from its PrismRA precision medicine diagnostic and expand the Atropos Evidence™ Network, enhancing the immunology multimodal network on Atropos Health’s GENEVA OS™.   #PrecisionMedicine #AutoimmuneDisease #RheumatoidArthritis #RealWorldEvidence #ArtificialIntelligence   Link: https://lnkd.in/eESkfJTY

Common Cough Syrup Ingredient Could Treat a Serious Lung Disease: EMBL scientists uncover potential use of an FDA-approved over-the-counter cough syrup ingredient to treat fibrotic lung disease. A common ingredient in many over-the-counter cough syrups, dextromethorphan, may hold promise as a treatment for lung fibrosis—a condition associated with various serious health issues. Researchers from EMBL Heidelberg, working in collaboration with other scientists, have identified dextromethorphan as a potential therapy for lung fibrosis. Their findings, published in Science Translational Medicine, reveal that dextromethorphan can reduce lung fibrosis by interfering with the production of collagen that leads to scarring within cells. Understanding Lung Fibrosis: Lung fibrosis – caused by an excess amount of scarring, formed when fibrillar collagen accumulates in the lung – most often occurs in older adults for a variety of reasons: exposure to environmental irritants such as asbestos, coal dust, and mold; as a side effect from chemotherapy agents; as a long-term consequence from serious lung disease such as tuberculosis; and as part of certain autoimmune or inflammatory diseases, such as lupus or rheumatoid arthritis.

📢📢📢Watch the replay: https://lnkd.in/ek4qbSwH We had a record-breaking number of audiences with InScienceWeTrust Community for #Bioverse EP13! This is THE episode you cannot miss for great insights into the science and recent deal-making in #ImmunologyandInflammation (I&I)!   Below are some takeaways from our expert panel discussion featuring David W. Shen, Kaveri Pohlman, PhD, MBA, and David Gu. We highly recommend that you watch our replay to get the full experiences of industry senior leaders.    💡 On differentiators for I&I: David W. Shen noted the immune system’s dual nature and I&I disease's chronicity which demand safe, long-term therapies. Kaveri Pohlman, PhD, MBA mentioned the flip-side-of-cancer characteristics of I&I and the recent trend toward precision medicine, emphasizing the heterogeneity and opportunities in I&I using an example of Lupus/SLE to illustrate the many targets for development. David Gu also noted the recent heat in I&I and the trend toward exploring new biology and new mechanisms.   💡On fueling the recent I&I R&D and deal boom: Kaveri Pohlman, PhD, MBA highlighted several elements such as market opportunities, technological advancements, more favorable trial designs compared to oncology, and room for differentiated commercial strategies. David Gu brought up the influx of investment and new drug targets and characterized I&I as a high-reward, low-risk area. David W. Shen commented on factors including scientific advancements and chronicity, highlighting biologics’ advantage in safety and convenience.   💡On emerging target/modality and disease areas: Kaveri Pohlman, PhD, MBA discussed blockbuster opportunities for both new and validated targets/modalities, stressing that disease area strategy plays a critical role in development. She also delved into emerging modalities such as T-cell engagers and many cell therapies, highlighting engineered Tregs as a hot modality for deal-making.   💡On bispecifics’ popularity in I&I: David W. Shen commented on TSLP’s involvement in Th2 and non-Th2 pathways and its potential for treating asthma. The efficacy enhancement was achieved by incorporating IL-13, whose synergistic effect was identified by analyzing trial data. David Gu also emphasized the synergistic effect of bispecifics, particularly in T-cell engagers, which are gaining traction in autoimmune and oncology fields.   💡On the JNJ/Proteologix $850M acquisition and the Candid/Epimab TCE deal: David W. Shen shared the three-year journey from launch to acquisition, focusing on the fundraising challenges during industry downturn and investor’s hesitation due to past TSLP failures. His remark on the deal was to have “all the stars aligned” with differentiation and momentum as critical factors. David Gu discussed Epimab/Vignette’s BCMA/CD3 asset in Candid’s $370M launch; he emphasized that robust clinical data was instrumental to the success and noted the pivotal role of leadership, deal execution, and investor backing.

I think I also broke my LinkedIn post length record when typing the notes, as this webinar was so informative. Check out the replay (link below) to get all the good stuff for I&I.

Exciting Progress for Those Affected by Unexplained Sicca Syndrome! I'm thrilled to share news about a recent study published in Clinical Rheumatology that could be a game-changer for individuals struggling with unexplained sicca syndrome. Researchers have identified new biomarkers associated with the condition, paving the way for more accurate diagnoses and targeted treatments. While these biomarkers aren't available for routine clinical use just yet, their discovery is a significant step forward. Once integrated into clinical practice, they have the potential to provide much-needed answers and hope to those affected by this often misunderstood condition. Kudos to the dedicated researchers pushing the boundaries of medical science. Here's to a future where unexplained sicca syndrome can be better understood and managed! #SiccaSyndrome #MedicalResearch #Biomarkers #HopeInHealthcare https://lnkd.in/gwCH-8cg

We are proud to announce the launch of new clinico-genomic datasets to enable life science companies to drive precision medicine drug discovery and development. Built through Helix’s extensive health system partnerships, these population-scale cohorts consist of full longitudinal clinical and genomic records that span multiple therapeutic areas including Cardiovascular, Immunology & Inflammation and Metabolic conditions. Helix CEO and co-founder James Lu, M.D. Ph.D: “As the number of precision therapies in development continues to rapidly expand, clinico-genomic data provide incredible opportunities to develop targeted therapeutics with better safety and efficacy profiles.” Hylton Kalvaria, Chief Commercial Officer of Helix: “Life science researchers can utilize Helix’s diverse clinico-genomic cohorts to better understand genetic factors associated with disease progression and clinical outcomes, as well as validating therapeutic candidates of interest.” #lifesciences #genomics #drugdiscovery #precisionmedicine You can read more about today’s announcement here: https://bwnews.pr/4b0Grip

#SpeakingofScience: Congratulations to Helix on the launch of groundbreaking Clinic-Genomic Datasets! These #datasets—created through partnerships with diverse U.S. #health systems—will propel #precisionmedicine #drugdiscovery and development. Importantly, the datasets include rich longitudinal #clinical and #genomic records spanning #cardiovascular, #immunology and #inflammation, #metabolic conditions, and more. 🌟 Key Benefits include: Access to Exome+® sequencing data for over 125,000 patients; a diverse #Cardiometabolic cohort with 50k+ patient; and a deeper understanding of #genetic factors in disease progression and validate therapeutic candidates. Discover how Helix is revolutionizing precision medicine and paving the way for personalized treatments at the link below! #PrecisionMedicine #Genomics #Helix #ClinicalResearch #Innovation #MedicalResearch #GeneticResearch #BioTech #Healthcare #HealthcareInnovation

Speaking of #Multigenics...New developments in CVD medicine 🫀🔬 The review linked below examines new/innovative approaches to treating atherosclerosis by targeting MULTIPLE (key term) inflammatory pathways. Cardiovascular diseases are a perfect example of complex multi-pathway/multi-gene diseases - burdened by a complex smattering of inflammation, cellular damage, and more. However, new opportunities for more effective treatments are emerging spearheaded by the concept of targeting multiple pathways/genes simultaneously and/or using multi-modal approaches. Key paper insights: • Multiple inflammatory mediators contribute to atherosclerosis progression - and therefore should be addressed simultaneously • Recent clinical trials show promise in targeting specific inflammatory pathways • Combining therapies to address multiple inflammatory targets could enhance efficacy • Personalized approaches based on individual inflammatory profiles are on the horizon Any multi-pronged approach should be celebrated as progress. We must absolutely move away from old modes of thinking that one gene could have a significant effect against a complex disease. Read more here: https://lnkd.in/dc24gxv2 #ThinkMultigenic #MultigenicTherapeutics #HeartDisease #GeneTherapy #CellTherapy #PersonalizedMedicine #Atherosclerosis #DrugDiscovery

#Inflammatorydiseases represent a growing and significant concern in global healthcare, yet many conditions remain poorly understood and under-researched. Expert Review of Clinical Immunology is curating an article collection which aims to highlight these gaps in knowledge, specifically focusing on understudied inflammatory diseases. Are you currently researching a topic that would be suitable? ⚕️   While many inflammatory conditions, such as rheumatoid arthritis and inflammatory bowel disease receive considerable attention, many rare, emerging, or poorly defined inflammatory disorders remain underrepresented in current research. These diseases often present unique challenges in diagnosis, treatment, and patient care, emphasising the urgent need for deeper investigation and understanding.   Featuring contributions from key opinion leaders across academia and industry, this Article Collection will explore the latest research on rare, emerging, and neglected inflammatory diseases. By bringing these overlooked conditions into focus, we aim to inspire further investigation and address critical unmet needs within clinical immunology.   The scope of this Collection includes, but is not limited to, the following areas: • Rare and orphan inflammatory diseases • Novel or atypical presentations of inflammatory conditions • Inflammatory diseases understudied in specific populations • Emerging diseases with inflammatory components • Unexplored sex, genetic, epigenetic, or environmental factors contributing to inflammation • Advances in diagnostic biomarkers, imaging techniques, or tools for understudied inflammatory diseases • Innovative therapeutic approaches • Understudied #autoimmune, #autoinflammatory, #chronicinflammatory, #infectiousinflammatory, and #allergicdiseases   We encourage authors to submit relevant editorials, reviews, perspectives, drug profiles, and original research. The benefit of publishing as part of an Article Collection is that they often become a key resource, driving a research community forward. This has a synergistic effect on every article in the Collection. The articles often receive more views and higher citation numbers as the Collections receive increased promotion via social media and our marketing team.   If you are interested in contributing or would like more information, please contact the Commissioning Editor, Amelia Dennis, at hyperlink amelia.dennis@tandf.co.uk.   https://lnkd.in/eaGwHFd7